1
|
Blum K, Mclaughlin T, Gold MS, Gondre-Lewis MC, Thanos PK, Elman I, Baron D, Bowirrat A, Barh D, Khalsa J, Hanna C, Jafari N, Zeine F, Braverman ER, Dennen C, Makale MT, Makale M, Sunder K, Murphy KT, Badgaiyan RD. Are We Getting High Cause the Thrill is Gone? JOURNAL OF ADDICTION PSYCHIATRY 2023; 7:5-516. [PMID: 38164471 PMCID: PMC10758019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/03/2024]
Abstract
In the USA alone, opioid use disorder (OUD) affects approximately 27 million people. While the number of prescriptions may be declining due to increased CDC guidance and prescriber education, fatalities due to fentanyl-laced street heroin are still rising. Our laboratory has extended the overall concept of both substance and non-substance addictive behaviors, calling it "Reward Deficiency Syndrome (RDS)." Who are its victims, and how do we get this unwanted disorder? Is RDS caused by genes (Nature), environment (Neuro-epigenetics, Nurture), or both? Recent research identifies resting-state functional connectivity in the brain reward circuitry as a crucial factor. Analogously, it is of importance to acknowledge that the cumulative discharge of dopamine, governed by the nucleus accumbens (NAc) and modulated by an array of additional neurotransmitters, constitutes a cornerstone of an individual's overall well-being. Neuroimaging reveals that high-risk individuals exhibit a blunted response to stimuli, potentially due to DNA polymorphisms or epigenetic alterations. This discovery has given rise to the idea of a diminished 'thrill,' though we must consider whether this 'thrill' may have been absent from birth due to high-risk genetic predispositions for addiction. This article reviews this issue and suggests the general concept of the importance of "induction of dopamine homeostasis." We suggest coupling a validated genetic assessment (e.g., GARS) with pro-dopamine regulation (KB220) as one possible frontline modality in place of prescribing potent addictive opioids for OUD except for short time harm reduction. Could gene editing offer a 'cure' for this undesirable genetic modification at birth, influenced by the environment and carried over generations, leading to impaired dopamine and other neurotransmitter imbalances, as seen in RDS? Through dedicated global scientific exploration, we hope for a future where individuals are liberated from pain and disease, achieving an optimal state of well-being akin to the proverbial 'Garden of Eden'.
Collapse
Affiliation(s)
- Kenneth Blum
- The Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA
- Center for Sports, Exercise, Psychiatry, Western University Health Sciences, Pomona, CA, USA
- Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
- Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel
- The Sunder Foundation, Palm Springs, CA, USA
- Department of Psychiatry, University of Vermont School of Medicine, Burlington, VY, USA
- Department of Psychiatry, Wright University, Boonshoff School of Medicine, Dayton, OH, USA
- Division of Personalized Medicine, Cross-Cultural Research and Educational Institute, San Clemente, CA, USA
- Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur, West Bengal, India
| | - Thomas Mclaughlin
- The Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA
| | - Mark S. Gold
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | | | - Panayotis K. Thanos
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addiction, Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, USA
| | - Igor Elman
- Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA
| | - David Baron
- Center for Sports, Exercise, Psychiatry, Western University Health Sciences, Pomona, CA, USA
| | - Abdalla Bowirrat
- Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel
| | - Debamyla Barh
- Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur, West Bengal, India
| | - Jag Khalsa
- Division of Therapeutics and Medical Consequences, Medical Consequences of Drug Abuse and Infections Branch, NIDA-NIH, Special Volunteer, Gaithersburg, MD, USA
| | - Colin Hanna
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addiction, Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, USA
| | - Nicole Jafari
- Division of Personalized Medicine, Cross-Cultural Research and Educational Institute, San Clemente, CA, USA
- Department of Applied Clinical Psychology, The Chicago School of Professional Psychology, Los Angeles, CA, USA
| | - Foojan Zeine
- Department of Health Science, California State University at Long Beach, Long Beach, CA, USA
- Awareness Integration Institute, San Clemente, CA, USA
| | - Eric R. Braverman
- The Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA
| | - Catherine Dennen
- Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA
| | - Milan T. Makale
- Department of Radiation Medicine and Applied Sciences, UC San Diego, La Jolla, CA, USA
| | - Miles Makale
- Department of Psychology, UC San Diego, La Jolla, CA, USA
| | - Keerthy Sunder
- The Sunder Foundation, Palm Springs, CA, USA
- Department of Psychiatry, University of California Riverside, Riverside, CA, USA
| | - Kevin T. Murphy
- Department of Radiation Oncology, University of California, San Diego, La Jolla, USA
| | | |
Collapse
|